Vitamin D analogue-based therapies for psoriasis

Drugs of Today

Volumn 46, Issue 5, 2010, Pages 351-360

  O'Neill, J L ^a   Feldman, S R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

22 OXACALCITRIOL; BETA DEFENSIN 2; BETA DEFENSIN 3; BETAMETHASONE DIPROPIONATE; BETAMETHASONE VALERATE; CALCIPOTRIOL; CALCITRIOL; COLECALCIFEROL; CORTICOSTEROID DERIVATIVE; CYCLIC AMP; CYCLOSPORIN; POLYPEPTIDE ANTIBIOTIC AGENT; TACALCITOL; TACLONEX; TAZAROTENE; UNCLASSIFIED DRUG; VECTICAL; DERMATOLOGICAL AGENT; DRUG DERIVATIVE;

CELL DIFFERENTIATION; CELL PROLIFERATION; COST EFFECTIVENESS ANALYSIS; DRUG EFFICACY; DRUG MECHANISM; DRUG TOLERABILITY; FOLLICULITIS; HUMAN; HYPERCALCEMIA; INFLAMMATION; PATIENT COMPLIANCE; PHOTOTHERAPY; PRURITUS; PSORIASIS VULGARIS; RADIOACTIVITY; RECEPTOR BINDING; REVIEW; SKIN IRRITATION; SYSTEMIC THERAPY; TOPICAL TREATMENT; ULTRAVIOLET B RADIATION; VITAMIN BLOOD LEVEL; VITAMIN METABOLISM; ANIMAL; DRUG EFFECT; DRUG INTERACTION; INTRADERMAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PSORIASIS; SKIN;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHOLECALCIFEROL; DERMATOLOGIC AGENTS; DRUG INTERACTIONS; HUMANS; MEDICATION ADHERENCE; PSORIASIS; SKIN;

EID: 77954728556     PISSN: 16993993     EISSN: 16994019     Source Type: Journal    
DOI: 10.1358/dot.2010.46.5.1473264     Document Type: Review

References (41)

1. Rizova, E., Corroller, M. Topical calcitriol-studies on local tolerance and systemic safety. Br J Dermatol 2001,144 (Suppl 58): 3-10. (Pubitemid 32374822)
2. Barker, J.N., Berth-Jones, J., Groves, R., Omerod, A.D., Rizova, E., Griffiths, C.E. Calcium homeostasis remains unaffected after 12 weeks' therapy with calcitriol 3 microg/g ointment; no correlation with extent of psoriasis. J Dermatolog Treat 2003, 14(1): 14-21.
3. Carboni, I., de Felice, C., Bergamin, A., Chimenti, S. Topical use of calcitriol 3 microg/g ointment in the treatment of mild-to-moderate psoriasis: results from an open-label study. J Eur Acad Dermatol Venereol 2005, 19(Suppl. 3): 11-3.
4. Lehmann, B. Role of the vitamin D3 pathway in healthy and diseased skin-facts, contradictions and hypotheses. Exp Dermatol 2009, 18(2): 97-108.
5. Milde, P., Hauser, U., Simon, T. et al. Expression of 1,25-dihydroxyvitamin D3 receptors in normal and psoriatic skin. J Invest Dermatol 1991, 97(2): 230-9.
6. Peter, C.M., van de Kerkhof, P.C. Psoriasis. In: Dermatology. J. Bolognia, J. Jorizzo, R. Rapini (Eds.). Mosby: London, New York, 2003.
7. Gniadecki, R. Stimulation versus inhibition of keratinocyte growth by 1,25-Dihydroxyvitamin D3: dependence on cell culture conditions. J Invest Dermatol 1996, 106(3): 510-6.
8. Gerritsen, M.J., RuLo, H.FL, Van Vlijmen-Willems, I., Van Erp, P.E., van de Kerkhof, P.C. Topical treatment of psoriatic plaques with 1,25-dihydroxyvitamin D3: a cell biological study. Br J Dermatol 1993, 128(6): 666-73. (Pubitemid 23172026)
9. Tiberio, R., Bozzo, C., Pertusi, G. et al. Calcipotriol induces apoptosis in psoriatic keratinocytes. Clin Exp Dermatol 2009, 34(8): e972-e974.
10. Manggau, M., Kim, D.S., Ruwisch, L. et al. 1Alpha,25-dihydroxyvitamin D3 protects human keratinocytes from apoptosis by the formation of sphingosine-1-phosphate. J Invest Dermatol 2001, 117(5): 1241-9.
11. Sigmundsdottir, H., Pan, J., Debes, G.F. et al. DCs metabolize sunlight-induced vitamin D3 to 'program'T cell attraction to the epidermal chemokine CCL27. Nat Immunol 2007, 8(3): 285-93.
12. Gorman, S., Kuritzky, L.A., Judge, M.A. et al. Topically applied 1,25-dihydroxyvitamin D3 enhances the suppressive activity of CD4+CD25+ cells in the draining lymph nodes. J Immunol 2007, 179(9): 6273-83.
13. Peric, M., Koglin, S., Dombrowski, Y. Vitamin D analogs differentially control antimicrobial peptide/"alarmin"expression in psoriasis. PLoS One 2009, 4(7): e6340.
14. Wang, T.T., Nestel, F.P., Bourdeau, V. Cutting edge: 1,25- dihydroxyvitamin D3 is a direct inducer of antimicrobial peptide gene expression. J Immunol 2004, 173(5): 2909-12.
15. Zasloff, M. Sunlight, vitamin D, and the innate immune defenses of the human skin. J Invest Dermatol 2005, 125(5): xvi-xvii.
16. Klein, G.L., Chen, T.C., Holick, M.F. Synthesis of vitamin D in skin after burns. Lancet 2004, 363(9405): 291-2.
17. Langner, A., Ashton, P., van de Kerkhof, P.C., Verjans, H. A long-term multicentre assessment of the safety and tolerability of calcitriol ointment in the treatment of chronic plaque psoriasis. Br J Dermatol 1996, 135(3): 385-9. (Pubitemid 26297832)
18. Cullen, S.I. Long-term effectiveness and safety of topical calcipotriene for psoriasis. Calcipotriene Study Group. South Med J 1996, 89(11): 1053-6.
19. Mason, J., Mason, A.R., Cork, M.J. Topical preparations for the treatment of psoriasis: a systematic review. Br J Dermatol 2002, 146(3): 351-64.
20. Pinheiro, N. Comparative effects of calcipotriol ointment (50 micrograms/g) and 5% coal tar/2% allantoin/0.5% hydrocortisone cream in treating plaque psoriasis. Br J Clin Pract 1997, 51(1): 16-9.
21. Veien, N.K., Bjerke, J.R., Rossmann-Ringdahl, I., Jakobsen, H.B. Once daily treatment of psoriasis with tacalcitol compared with twice daily treatment with calcipotriol. A double-blind trial. Br J Dermatol 1997, 137(4): 581-6.
22. Zhu, X., Wang, B., Zhao, G. An investigator-masked comparison of the efficacy and safety of twice daily applications of calcitriol 3 microg/g ointment vs. calcipotriol 50 microg/g ointment in subjects with mild to moderate chronic plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007, 21(4): 466-72.
23. Ortonne, J.P., Humbert, P., Nicolas, J.F. Intra-individual comparison of the cutaneous safety and efficacy of calcitriol 3 microg g(-1) ointment and calcipotriol 50 microg g(-1) ointment on chronic plaque psoriasis localized in facial, hairline, retroauricular or flexural areas. Br J Dermatol 2003, 148(2): 326-33.
24. Lebwohl, M., Menter, A., Weiss, J. Calcitriol 3 microg/g ointment in the management of mild to moderate plaque type psoriasis: results from 2 placebo-controlled, multicenter, randomized double-blind, clinical studies. J Drugs Dermatol 2007, 6(4): 428-35.
25. Bourke, J.F., Iqbal, S.J., Hutchinson, P.E. A randomized double-blind comparison of the effects on systemic calcium homeostasis of topical calcitriol (3 micrograms/g) and calcipotriol (50 micrograms/g) in the treatment of chronic plaque psoriasis vulgaris. Acta Derm Venereol 1997, 77(3): 228-30.
26. Kragballe, K. The use of vitamin D analogues in dermatology. Curr Opin Dermatol 1995, 16:198-203.
27. Prignano, F., Buggiani, G., Lotti, T. Clinical evaluation of topical tacalcitol efficacy in extending the remission period between nb-UVB phototherapy cycles in psoriatic patients. Acta Biomed 2009, 80(1): 51-6.
28. Syuto, T., Ishibuchi, H., Sogabe, Y., Yokoyama, Y., Ishikawa, O. Efficacy of high-concentration tacalcitol ointment in psoriasis vulgaris after changing from other high-concentration vitamin D3 ointments. Dermatol Online J 2008, 14(2): 2.
29. Barker, J.N., Ashton, R.E., Marks, R., Harris, R.I, Berth-Jones, J. Topical maxacalcitol for the treatment of psoriasis vulgaris: a placebo-controlled, double-blind, dose-finding study with active comparator. Br J Dermatol 1999, 141(2): 274-8.
30. Abe, J., Morikawa, M., Miyamoto, K. et al. Synthetic analogues of vitamin D3 with an oxygen atom in the side chain skeleton. A trial of the development of vitamin D compounds which exhibit potent differentiation-inducing activity without inducing hypercalcemia. FEBS Lett 1987, 226(1): 58-62.
31. Saraceno, R., Andreassi, L., Ayala, F. et al. Efficacy, safety and quality of life of calcipotriol/betamethasone dipropionate (Dovobet) versus calcipotriol (Daivonex) in the treatment of psoriasis vulgaris: a randomized, multicentre, clinical trial. J Dermatolog Treat 2007, 18(6): 361-5.
32. Kerscher, M., Volkenandt, M., Plewig, G., Lehmann, P. Combination phototherapy of psoriasis with calcipotriol and narrow-band UVB. Lancet 1993, 342(8876): 923. (Pubitemid 23291600)
33. Woo, W.K., McKenna, K.E. Combination TLO1 ultraviolet B phototherapy and topical calcipotriol for psoriasis: a prospective randomized placebo-controlled clinical trial. Br J Dermatol 2003, 149(1): 146-50.
34. Takekoshi, T., Asahina, A., Komine, M., Tamaki, K. Treatment of psoriasis vulgaris with narrow-band UVB and topical Maxocalcitol. Acta Derm Venereol 2006, 86(4): 375-6.
35. Queille-Roussel, C., Duteil, L., Parneix-Spake, A., Arsonnaud, S., Rizova, E. The safety of calcitriol 3 microg/g ointment. Evaluation of cutaneous contact sensitization, cumulative irritancy, photoallergy contact sensitization and phototoxicity. Eur J Dermatol 2001, 11(3): 219-24.
36. Lebwohl, M.G., Corvari, L. Compatibility of topical therapies for psoriasis: Challenges and innovations. Cutis 2007, 79(1 Suppl 2): 5-10.
37. Patel, B., Siskin, S., Krazmien, R., Lebwohl, M. Compatibility of calcipotriene with other topical medications. J Am Acad Dermatol 1998, 38(6 Pt 1): 1010-1.
38. Huang, X., Tanojo, H., Lenn, J., Deng, C.H., Krochmal, L. A novel foam vehicle for delivery of topical corticosteroids. J Am Acad Dermatol 2005, 53(1, Suppl. 1): S26-S38.
39. Sander, H.M., Morris, L.F., Phillips, C.M., Harrison, P.E., Menter, A. The annual cost of psoriasis. J Am Acad Dermatol 1993, 28(3): 422-5.
40. Augustin, M., Peeters, P., Radtke, M., Moehling, U., Lapp, C. Cost-effectiveness model of topical treatment of mild to moderate psoriasis vulgaris in Germany. A comparison of cal] cipotriol/betamethasone (Daivobet/Dovobet/Taclonex) once daily and a morning/evening non-fix combination of calcipotriol and betamethasone. Dermatology 2007, 215(3): 219-28.
41. Bottomley, J.M., Auland, M.E., Morais, J., Boyd, G., Douglas, W.S. Cost-effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate compared with commonly used topical treatments in the management of moderately severe plaque psoriasis in Scotland. Curr Med Res Opin 2007, 23(8): 1887-901.